TENDOCOLINN®

TENDOCOLINN® is a dietary supplement with specific bioactive collagen peptides obtained from hydrolysed bovine collagen, dry extract of acerola fruit and vitamin B6. Bioactive collagen peptides in the patented formulation Tendoforte®B stimulate the creation of collagen, proteoglycans and elastin, which provides for firmness, strength, better mobility and elasticity of tendons and ligaments.

Why TENDOCOLINN®?

In which conditions is the administration of TENDOCOLINN® recommended?

What does TENDOCOLINN®contain?

Active ingredients
1 sachet (daily dose)
TENDOFORTE®B (bioactive collagen peptides)
5 g
Dry extract of acerola fruit (Malpighia punicifolia L.)
120 mg
out of that, Vitamin C
30 mg
Vitamin B6
2 mg

TENDOFORTE®B

High single dose of specific bioactive collagen peptides restores the structure of tendons and ligaments, which speeds up the process of recovery after injury, maintains the function of ligaments and tendons, reduces the risk of recurrence of injuries in the form of sprains.

TENDOFORTE®B

High single dose of specific bioactive collagen peptides restores the structure of tendons and ligaments, which speeds up the process of recovery after injury, maintains the function of ligaments and tendons, reduces the risk of recurrence of injuries in the form of sprains.

VITAMIN C

Obtained from acerola, it contributes to the normal synthesis of collagen required for normal function of cartilage, tendons, ligaments and bones. It hydroxylates the amino acids that make up the collagen fibres, thus providing the strength and elasticity of the newly formed collagen fibres.

TENDOFORTE®B

High single dose of specific bioactive collagen peptides restores the structure of tendons and ligaments, which speeds up the process of recovery after injury, maintains the function of ligaments and tendons, reduces the risk of recurrence of injuries in the form of sprains.

VITAMIN B6

Coenzyme in over 150 enzymatic reactions in our body playing a significant role in the metabolism of proteins and carbohydrates, neutralizing the effect of free radicals and reducing the inflammation that accompanies sprains, ruptures and other injuries to tendons and ligaments.

TENDOFORTE®B

High single dose of specific bioactive collagen peptides restores the structure of tendons and ligaments, which speeds up the process of recovery after injury, maintains the function of ligaments and tendons, reduces the risk of recurrence of injuries in the form of sprains.

Tendoforte®B – clinical studies

Method of use

Dilute one sachet of powder a day in 200 ml of fluid and drink it.
Presentation: 28 sachets.
Flavour: orange.

1. Positive impact of bioactive collagen peptides to ligaments and tendons JISSN 15. 2018 2018

Study design: Randomized, double-blind, placebo-controlled, monocentric study with participation of 60 women and men athletes, (50 at the end of study). Diagnosis: chronic ankle instability (CAI) – CAIT≤24. The tested group was taking 5 g of Tendoforte®B, while placebo group was taking 5 g of maltodextrin every day. Therapy was administered for 6 months, the subjects were monitored for another 3 months. Additional prescribed therapy: 3 times a week by 10 minutes of exercise (squats, skipping rope), of the same intensity during the overall period of testing; supplementation 1h upon the completion of the exercises cycle.
Study results: After 6 months of continuous administration of the product Tendoforte®B there was a statistically significant increase of measured parameters values: stability of ankle was improved, increased endurance and reduced sense of pain. It was recorded at the examination done 3 months upon completion of therapy that 96% of patients from the group that was taking Tendoforte®B did not have repeated ankle sprains, 84% of them established complete joint stability, and the risk of new injuries significantly decreased.

2. Testing of efficiency of administration of Tendoforte®B in therapy of chronic Achilles tendinopathy, 2017;29(Suppl.):O26.

Study design:

Randomized, double-blind, placebo-controlled, cross-over study with participation of 20 subjects, professional runners with unilateral (n=7) or bilateral (n=13) clinical symptoms of mid-portion tendinopathy. Clinical diagnosis was established on the basis of 2-6 cm thickening of the tendon. They could not run and conventional therapy was not effective. Length of study was six months.

VISA-A which represents the parameter for the assessment of clinical seriousness of the condition of patients with chronic Achilles tendinopathy was monitored. It is a questionnaire for assessing symptoms and their impact on the patient’s physical condition and abilities. It contains 8 questions referring to pain, functionality and symptoms accompanying physical activity. Maximum score is 100. The study was reviewed at month 3 and month 6.

Study results: There is a statistically significant increase of VISA-A score (73.4) in a group that administered Tendoforte®B after 3 months of therapy. The group that switched to Tendoforte®B after 3 months of taking placebo had a statistically significant increase in VISA-A score (85.8) 6 months after the start of the study. After 3 months, 60% of subjects from the first group and 30% from the second group resumed the regular training sessions and running. After 6 months this number increased to 70% from the first and 50% from the second group.

1. Positive impact of bioactive collagen peptides to ligaments and tendons JISSN 15. 2018 2018

Study design: Randomized, double-blind, placebo-controlled, monocentric study with participation of 60 women and men athletes, (50 at the end of study). Diagnosis: chronic ankle instability (CAI) – CAIT≤24. The tested group was taking 5 g of Tendoforte®B, while placebo group was taking 5 g of maltodextrin every day. Therapy was administered for 6 months, the subjects were monitored for another 3 months. Additional prescribed therapy: 3 times a week by 10 minutes of exercise (squats, skipping rope), of the same intensity during the overall period of testing; supplementation 1h upon the completion of the exercises cycle.
Study results: After 6 months of continuous administration of the product Tendoforte®B there was a statistically significant increase of measured parameters values: stability of ankle was improved, increased endurance and reduced sense of pain. It was recorded at the examination done 3 months upon completion of therapy that 96% of patients from the group that was taking Tendoforte®B did not have repeated ankle sprains, 84% of them established complete joint stability, and the risk of new injuries significantly decreased.

2. Testing of efficiency of administration of Tendoforte®B in therapy of chronic Achilles tendinopathy, 2017;29(Suppl.):O26.

Study design:

Randomized, double-blind, placebo-controlled, cross-over study with participation of 20 subjects, professional runners with unilateral (n=7) or bilateral (n=13) clinical symptoms of mid-portion tendinopathy. Clinical diagnosis was established on the basis of 2-6 cm thickening of the tendon. They could not run and conventional therapy was not effective. Length of study was six months.

VISA-A which represents the parameter for the assessment of clinical seriousness of the condition of patients with chronic Achilles tendinopathy was monitored. It is a questionnaire for assessing symptoms and their impact on the patient’s physical condition and abilities. It contains 8 questions referring to pain, functionality and symptoms accompanying physical activity. Maximum score is 100. The study was reviewed at month 3 and month 6.

Study results: There is a statistically significant increase of VISA-A score (73.4) in a group that administered Tendoforte®B after 3 months of therapy. The group that switched to Tendoforte®B after 3 months of taking placebo had a statistically significant increase in VISA-A score (85.8) 6 months after the start of the study. After 3 months, 60% of subjects from the first group and 30% from the second group resumed the regular training sessions and running. After 6 months this number increased to 70% from the first and 50% from the second group.